Basic Materials -
Chemicals - Specialty - NYSE - US
$ 51.45
-0.436 %
$ 2.43 B
Market Cap
-502.6
P/E
1. INTRINSIC VALUE
Balance Sheet
Ashland Inc.
| Current Assets | 1.2 B |
| Cash & Short-Term Investments | 300 M |
| Receivables | 227 M |
| Other Current Assets | 668 M |
| Non-Current Assets | 4.45 B |
| Long-Term Investments | 3 M |
| PP&E | 1.42 B |
| Other Non-Current Assets | 3.03 B |
| Current Liabilities | 490 M |
| Accounts Payable | 214 M |
| Short-Term Debt | 20 M |
| Other Current Liabilities | 256 M |
| Non-Current Liabilities | 2.29 B |
| Long-Term Debt | 1.45 B |
| Other Non-Current Liabilities | 839 M |
EFFICIENCY
Earnings Waterfall
Ashland Inc.
| Revenue | 2.11 B |
| Cost Of Revenue | 1.5 B |
| Gross Profit | 618 M |
| Operating Expenses | 644 M |
| Operating Income | -26 M |
| Other Expenses | -195 M |
| Net Income | 169 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ashland Inc.
| Net Income | 169 M |
| Depreciation & Amortization | 274 M |
| Capital Expenditures | -137 M |
| Stock-Based Compensation | 15 M |
| Change in Working Capital | 227 M |
| Others | 131 M |
| Free Cash Flow | 325 M |
Wall Street Analysts Price Targets
Ashland Inc.
Wall Street analysts predict an average 1-year price target for ASH of $94 , with forecasts ranging from
a
low of
$60 to a high of $118 .
ASH Lowest Price Target
Wall Street Target
60 USD
16.62%
ASH Average Price Target
Wall Street Target
94 USD
82.70%
ASH Highest Price Target
Wall Street Target
118 USD
129.35%
4. DIVIDEND
ANALYSIS
0.56%
DIVIDEND YIELD
0.405 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Ashland Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
115 K USD 2
6-9 MONTHS
482 K USD 1
9-12 MONTHS
0 USD 0
Bought
2.21 M USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ashland sets date for second-quarter fiscal 2025 earnings release and conference call webcast
WILMINGTON, Del., April 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its second-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Wednesday, April 30, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Thursday, May 1. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com.
globenewswire.com
- 2 weeks ago
Ashland Wraps Up Expansion of Pharmaceutical Plant in Brazil
ASH is investing in modernizing equipment for microbial protection in personal care applications at its Technical Center in Sao Paulo.
zacks.com
- 4 weeks ago
Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest
Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China
globenewswire.com
- 1 month ago
Ashland to host 2025 Innovation Day for analysts and investors
WILMINGTON, Del., March 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is hosting an Innovation Day for analysts and investors at the company's Bridgewater, New Jersey facility, Thursday, May 29, 2025. The event will showcase the enhanced capabilities and expanded applications of Ashland's scalable technology platforms. Registration is required, with options to attend via live webcast or in person.
globenewswire.com
- 1 month ago
Ashland Wraps Up Divestment of Avoca Business to Mane
ASH closes the sales of its Avoca business, the last entity remaining from the Pharmachem acquisition.
zacks.com
- 1 month ago
Ashland completes sale of Avoca business to Mane
Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed.
globenewswire.com
- 1 month ago
Ashland Presents Attractive Upside Emerging From The Downcycle
Ashland is generating attractive free cash flow and is well-positioned to achieve its 2027 target of $600 million EBITDA and 50% FCF conversion rate. Despite the stock selling off over the last 8 months, Ashland's strategic acquisitions and divestitures have strengthened its market position, with a focus on high-margin, patent-protected products. Ashland's strong balance sheet, low leverage, and fixed-rate debt provide stability and flexibility to navigate the current downcycle in the specialty chemicals sector.
seekingalpha.com
- 2 months ago
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism.
seekingalpha.com
- 2 months ago
Ashland's Earnings Outpace Estimates, Revenues Miss in Q1
Organic sales volume growth in ASH's Personal Care, Specialty Additives and Intermediates segments largely offset lower volumes in Life Sciences in Q1.
zacks.com
- 3 months ago
Ashland Inc. (ASH) Q1 2025 Earnings Call Transcript
Ashland Inc. (NYSE:ASH ) Q1 2025 Earnings Conference Call January 29, 2025 9:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo Chris Parkinson - Wolfe Research John Roberts - Mizuho David Begleiter - Deutsche Bank Jeff Zekauskas - JPMorgan Mike Harrison - Seaport Research Partners Bhavesh Lodaya - BMO Capital Markets Josh Spector - UBS Operator Good day and thank you for standing by. Welcome to the Ashland Inc. First Quarter 2025 Earnings Conference Call.
seekingalpha.com
- 3 months ago
New Strong Sell Stocks for January 29th
ARCAY, ASH and DNKEY have been added to the Zacks Rank #5 (Strong Sell) List on January 29, 2024.
zacks.com
- 3 months ago
Here's What Key Metrics Tell Us About Ashland (ASH) Q1 Earnings
Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
- 3 months ago
8. Profile
Summary
Ashland Inc. ASH
COUNTRY
US
INDUSTRY
Chemicals - Specialty
MARKET CAP
$ 2.43 B
Dividend Yield
0.56%
Description
Ashland Inc. provides additives and specialty ingredients worldwide. It operates through Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions. The Personal Care & Household segment provides a range of nature-based, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. The Intermediates and Solvents segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. Ashland Inc. was founded in 1924 and is based in Wilmington, Delaware.
Contact
8145 Blazer Drive, Wilmington, DE, 19808
https://www.ashland.com
IPO
Date
March 17, 1980
Employees
3200
Officers
Mr. Guillermo Novo
Chairman & Chief Executive Officer
Ms. Alessandra Faccin Assis
Senior Vice President and GM of Life Sciences & Intermediates
Mr. James P. Minicucci
Senior Vice President & GM of Personal Care
Ms. Robin E. Lampkin
Senior Vice President, General Counsel & Secretary
Mr. John Kevin Willis
Senior Vice President, Chief Financial Officer & Principal Accounting Officer
Dr. Osama M. Musa Ph.D.
Senior Vice President & Chief Technology Officer
Carolmarie C. Brown
Vice President of Corporate Affairs, Global Marketing, Brand & Business Communications
Mr. William C. Whitaker C.F.A.
Vice President of Finance & Director of Investor Relations
Ms. Eileen M. Drury
Senior Vice President & Chief HR Officer
Mr. Karl R. Bostaph
Senior Vice President of Operations